Generation of robust CD8\(^+\) T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes

Keri L. Schaubert\(^1,2\), David A. Price\(^3,4\), Janelle R. Salkowitz\(^1\), Andrew K. Sewell\(^4\), John Sidney\(^5\), Tedi E. Asher\(^3\), Sylvie E. Blondelle\(^6,7\), Sharon Adams\(^8\), Francesco M. Marincola\(^8\), Aviva Joseph\(^9\), Alessandro Sette\(^5\), Daniel C. Douek\(^3\), Velpandi Ayyavoo\(^10\), Walter Storkus\(^11\), Ming-Ying Leung\(^12\), Hwee L. Ng\(^13\), Otto O. Yang\(^13\), Harris Goldstein\(^9\), Darcy B. Wilson\(^6,7\) and June Kan-Mitchell\(^1,2\)

\(^1\) Department of Biological Sciences and Border Biomedical Research Institute, University of Texas at El Paso, El Paso, TX, USA
\(^2\) Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
\(^3\) Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
\(^4\) Department of Infection, Immunity and Biochemistry, Cardiff University School of Medicine, Cardiff, Wales, UK
\(^5\) La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA
\(^6\) Torrey Pines Institute for Molecular Studies, San Diego, CA, USA
\(^7\) Mixture Sciences Incorporated, San Diego, CA, USA
\(^8\) Immunogenetics Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA
\(^9\) Departments of Microbiology & Immunology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA
\(^10\) Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
\(^11\) Departments of Immunology and Dermatology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
\(^12\) Department of Mathematical Sciences, University of Texas at El Paso, El Paso, TX, USA
\(^13\) Department of Medicine and AIDS Institute, Center for Health Sciences, University of California, Los Angeles, CA, USA

HLA-A*0201-restricted virus-specific CD8\(^+\) CTL do not appear to control HIV effectively in vivo. To enhance the immunogenicity of a highly conserved subdominant epitope, TV9 (TLNAWVKVV, p24 Gag\(^19–27\)), mimotopes were designed by screening a large combinatorial nonapeptide library with TV9-specific CTL primed in vitro from healthy donors. A mimic peptide with a low binding affinity to HLA-A*0201, TV9p6 (KI\(^\text{NAW}\)IKVV), was studied further. Parallel cultures of in vitro-primed CTL showed that TV9p6 consistently activated cross-reactive and equally functional CTL as measured by cytotoxicity, cytokine production and suppression of HIV replication in vitro. Comparison of TCRB gene usage between CTL primed from the same donors with TV9 or TV9p6 revealed a degree of clonal overlap in some cases and an example of a conserved TCRB sequence encoded distinctly at the nucleotide level between individuals (a “public” TCR); however, in the main, distinct clonotypes were recruited by each peptide antigen. These findings indicate that mimotopes can mobilize functional cross-reactive clonotypes that are less readily recruited from the naïve T-cell pool by the corresponding WT epitope. Mimotope-induced repertoire diversification could potentially override subdominance under certain circumstances and enhance vaccine-induced responses to conserved but poorly immunogenic determinants within the HIV proteome.

Key words: Agonist peptide · CD8\(^+\) CTL · HIV vaccine · In vitro immunization

**Correspondence:** Dr. June Kan-Mitchell  
**e-mail:** jkanmitchell@utep.edu

© 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim  
www.eji-journal.eu
**Introduction**

Virus-specific CD8+ CTL play a central role in the control of HIV infection [1, 2]. However, the ability of such CTL to impose immune pressure on HIV varies according to specificity, with some responses seemingly exerting no influence on the virus [3]. Strong linkages have been reported between a few HLA-B class I alleles and control of infection [4]. The impact of these molecules on disease outcome is mediated largely by potent CTL activities that target highly conserved determinants [5], the majority of which reside within the p24 Gag protein [2]. Aside from their character, these CTL responses may be effective because the selected escape mutations exact a significant cost to viral fitness, thereby favoring the host even after immune evasion [2]. Thus, the issue of whether similar epitope targets restricted by common HLA alleles remain within the HIV proteome to allow for meaningful population coverage is fundamental to the prospects for a broadly applicable T-cell-based vaccine.

Virus-specific CTL responses restricted by the most prevalent allele, HLA-A*0201, do not appear to suppress HIV effectively in vivo [6], consistent with the notion that “inactive” epitopic forms may have been fixed in the circulating viral strains [7, 8]. Paradoxically, however, there is one well-defined epitope in p24 Gag (TV9, TLANWKV, residues 19–27) that shares many features in common with known protective determinants. Thus, TV9 is highly conserved across HIV clades, with only one common variant in which valine at position 9 is “conservatively” replaced by isoleucine [9]. This epitope resides in the first α-helix at the N-terminus of p24 and overlaps by five residues with the protective HLA-B*57-restricted ISPRTLNAW (IW9) determinant recognized early by slow progressors [10]. Despite the small number of reports of TV9 reactivity in patients, there are indications that CTL responses to this epitope can control virus [11]. Above all, an elevated and sustained TV9-specific response was noted in one person who remained uninfected despite parental exposure to a highly replicating HIV strain [12]. The functional sensitivity of the in vivo TV9 reactivity, a factor considered important for the inhibition of HIV in vivo [13], was also relatively high [11]. Thus, the potential of TV9 as a vaccine target deserves further exploration, particularly since there may be few alternatives within the HIV proteome for the most prevalent HLA class I allele.

Previously, we studied the pre-infection TCR repertoire for TV9 by priming naïve CD8+ T cells from healthy seronegative donors [11]. Stable, homogeneous and immunologically reactive TV9-specific CTL (TV9-CTL) cultures were generated from most donors, thereby suggesting that the cognate TCR repertoire is not limiting in HLA-A*0201 carriers. TV9-CTL were multifunctional and suppressed HIV replication in vitro. Thus, while in vitro immunization suggests that TV9 is potentially highly immunogenic, data from patients indicate that it would be necessary to devise immunization strategies that selectively elicit clonotypes with high functional sensitivities to overcome the typical subdominance of this epitope in the context of viral infection. Here, we identified mimic peptides (“mimotopes”) by probing a large positional scanning synthetic combinatorial nonapeptide library (PS-SCL) with homogeneous, well-characterized in vitro-primed TV9-CTL [14]. We selected a peptide, TV9p6 (KNAWIKKLV), with the lowest binding affinity to HLA-A*0201 for detailed analysis, reasoning that an unstable peptide-HLA-A*0201 complex and the attendant low epitope density would preferentially select clonotypes with high functional sensitivity. Parallel CD8+ T-cell cultures specific for TV9 and TV9p6 were established to compare specificity and cross-recognition based on functional assays that included cytolysis, cytokine production and suppression of HIV replication in vitro. Concomitant repertoire analyses were conducted using a quantitative molecular approach to evaluate antigen-driven clonotype selection in relation to these functional attributes.

**Results**

**Prediction of TV9 mimotopes by screening a positional scanning synthetic nonapeptide combinatorial library**

A polyclonal TV9-CTL culture (TV9-1, index culture) was screened for cytolytic activity with 180 nonapeptide library mixtures as described previously [14]. Each well contained 10^4 CTL and 2 × 10^3 3HCr-labeled TAP-deficient, HLA-A*0201-expressing T2 cells with 100 μg/mL of a peptide mixture. Significant and reproducible differences in lysis were observed between mixtures.

Figure 1A is representative of three scans performed. Remarkably, the percent lysis with some mixtures, each containing 1.7 × 10^10 peptides at femtomolar concentrations, was equivalent to that observed with the TV9 peptide (30–50% versus 60% at 1 μg/mL). However, T-cell activation may be achieved via degenerate stimulation by many peptides within each mixture [15].

Six mixtures defined with residues corresponding to the TV9 sequence (hollow bars) were among the most stimulatory mixtures for sublibraries within that position. They were L in position 2 (P2), N in P3, W in P5, V in P6 and P in P8 and P9. Results with the P2 and P9 anchor positions confirmed the power and accuracy of this assay. L and M are known preferred residues in P2 of HLA-A*0201 for detailed analysis, reasoning that an unstable peptide-HLA-A*0201 complex and the attendant low epitope density would preferentially select clonotypes with high functional sensitivity. Parallel CD8+ T-cell cultures specific for TV9 and TV9p6 were established to compare specificity and cross-recognition based on functional assays that included cytolysis, cytokine production and suppression of HIV replication in vitro. Concomitant repertoire analyses were conducted using a quantitative molecular approach to evaluate antigen-driven clonotype selection in relation to these functional attributes.

Figure 1A is representative of three scans performed. Remarkably, the percent lysis with some mixtures, each containing 1.7 × 10^10 peptides at femtomolar concentrations, was equivalent to that observed with the TV9 peptide (30–50% versus 60% at 1 μg/mL). However, T-cell activation may be achieved via degenerate stimulation by many peptides within each mixture [15].

Six mixtures defined with residues corresponding to the TV9 sequence (hollow bars) were among the most stimulatory mixtures for sublibraries within that position. They were L in position 2 (P2), N in P3, W in P5, V in P6 and P in P8 and P9. Results with the P2 and P9 anchor positions confirmed the power and accuracy of this assay. L and M are known preferred residues in P2 of HLA-A*0201; the scans showed that these mixtures were equally stimulatory. Likewise, mixtures that contained the preferred anchor residues in P9 (I, L and V) were almost equally active. N was the only stimulatory mixture in P3, suggesting that it may be a primary TCR contact site. P1 and P6 appeared degenerate, with at least five mixtures that were more effective than the TV9 sequence. Interestingly, the TV9p6 peptide with W in P4 (Fig. 1B) was the most stimulatory mixture that was more effective than the TV9 sequence. Interestingly, the TV9p6 peptide with W in P4 (Fig. 1B) was the most stimulatory mixture that was more effective than the TV9 sequence. Interestingly, the TV9p6 peptide with W in P4 (Fig. 1B) was the most stimulatory mixture that was more effective than the TV9 sequence. Interestingly, the TV9p6 peptide with W in P4 (Fig. 1B) was the most stimulatory mixture that was more effective than the TV9 sequence. Interestingly, the TV9p6 peptide with W in P4 (Fig. 1B) was the most stimulatory mixture that was more effective than the TV9 sequence.
Recognition of candidate peptides by TV9-CTL cultures

The candidate peptides were tested for recognition by TV9-CTL from five donors. Cytotoxicity was measured at four concentrations (1, 10, 100 and 1000 ng/mL) to estimate relative antigenicity. A peptide was considered cross-recognized if it elicited ≥ 50% of the lysis observed at the two highest concentrations of TV9.

Thirteen of the 48 peptides tested (27%) were cross-recognized by TV9-1 CTL and by at least one other culture (group I, Table 1). Four peptides (TV9p6, TV9p29, TV9p30 and TV9p18) were recognized by all cultures. The ability of non-index TV9-CTL to recognize 6–28 peptides encoding two to five substitutions suggests that recognition of the TV9/HLA-A*0201 complex is quite degenerate. Curiously, TV9-2 and TV9-4 CTL were sensitized by 6 and 18 sequences not recognized by index CTL (group II, Table 1), thereby suggesting differences in the degree of repertoire overlap between donors.

Immunogenicity of four broadly cross-recognized peptides

The ability of the first four peptides listed in Table 1 to prime TV9-cross-reactive CTL was determined (Fig. 2). TV9p30 was not immunogenic in three different donors (data not shown). TV9p6 immunized CTL (TV9p6-2, TV9p6-5, TV9p6-6 and TV9p6-7) that cross-recognized TV9 consistently (Fig. 2A). TV9p5 was also immunogenic and elicited TV9-cross-reactive CTL from two donors (Fig. 2B). TV9p29 was immunogenic but induced cross-reactive CTL from only one of two cultures (p29-8, Fig. 2C). That double to quadruple substituted mimotopes stimulated cross-reactive CTL is consistent with our contention that the available naive T-cell pool for TV9 may be broad [11].

Binding affinities of TV9 and its analogs to HLA-A2 class I antigens

Table 2 shows the binding affinities of TV9 and its mimotopes to members of the HLA-A2 supertype. Since HIV-specific CTL epitopes restricted by protective HLA-B alleles [17] show lower average peptide binding affinities than those of non-protective HLA-A-restricted epitopes [18], we selected TV9p6 with the lowest affinity to determine whether it is possible to consolidate the TV9 response around higher avidity clonotypes.

CD8+ cultures to TV9p6 and to TV9

Parallel CD8+ cultures to TV9p6 or TV9 were generated from four donors and induction of peptide-specific T cells was monitored with

Figure 1. Scanning a nonapeptide PS-SCL to identify TV9 agonist peptides. (A) Index TV9-1 cytotoxicity elicited by the 180 mixtures of a nonapeptide PS-SCL. Each graph, designated p1–p9, represents a set of 20 mixtures having the defined amino acid listed on the x-axis at a given position. The y-axis denotes the percentage lysis of T2 cells in the presence of each mixture. The hollow bars represent the native TV9 amino acid sequence. Each mixture was assayed in triplicate and scanning was repeated three times. (B) Design of 48 candidate peptides. The rationale for the selection of a particular active mixture in each position is discussed in the text.
### Table 1. Recognition of predicted candidate peptides, presented by T2 target cells, by the index and four allogeneic HLA-A*0201+ TV9-CTL cultures as determined by cytotoxicity a)

<table>
<thead>
<tr>
<th>Candidate peptide name and sequence</th>
<th>Resides substituted</th>
<th>% lysis at peptide concentrations (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TV9-1 (index)</td>
<td>TV9-3</td>
</tr>
<tr>
<td>Native</td>
<td>1 10 100 1000</td>
<td>1 10 100 1000</td>
</tr>
<tr>
<td>Group I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TV9</td>
<td>3 18 42 50</td>
<td>19 73</td>
</tr>
<tr>
<td>TV9-1 (index)</td>
<td>0 6 29 45</td>
<td>2 36 80</td>
</tr>
<tr>
<td>TV9-2</td>
<td>0 8 31 41</td>
<td>34 73 77</td>
</tr>
<tr>
<td>TV9-3</td>
<td>15 37 47 64</td>
<td>29 63 77</td>
</tr>
<tr>
<td>TV9-4</td>
<td>0 20 44 51</td>
<td>64 89 97</td>
</tr>
<tr>
<td>TV9-5</td>
<td>4 2 7 47 54</td>
<td>11 24 29</td>
</tr>
<tr>
<td>Group II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TV9</td>
<td>4 33 64 61</td>
<td>56 83 86</td>
</tr>
<tr>
<td>TV9-1 (index)</td>
<td>0 17 39 46</td>
<td>33 73 78</td>
</tr>
<tr>
<td>TV9-2</td>
<td>0 0 21 36 50</td>
<td>6 52 76</td>
</tr>
<tr>
<td>TV9-3</td>
<td>1 4 24 47</td>
<td>1 6 35</td>
</tr>
<tr>
<td>TV9-4</td>
<td>4 17 30 47</td>
<td>2 6 30</td>
</tr>
<tr>
<td>TV9-5</td>
<td>0 2 24 43</td>
<td>0 4 11</td>
</tr>
</tbody>
</table>

a) Positive recognition for TV9 and reactive artificial sequences is boldfaced and shaded. nd, not determined.

No. of the 48 artificial sequences recognized: 14 16 6 28 6
tetramers (Fig. 3). For donors 2, 6 and 7, the results were similar (Fig. 3A–C). TV9p6-specific T cells were detected as early as day 20. By day 35, the TV9p6-cultures were essentially homogeneous by tetramer staining. Moreover, the staining patterns of TV9p6-T cells with both TV9p6 and TV9 tetramers were essentially identical, indicating that TV9p6-T cells recognized TV9. Parallel TV9-cultures showed ~90% TV9-T cells by day 40.

Differential tetramer staining was observed in the TV9p6-8 culture (Fig. 3D). The majority (74%) of the cells stained intensely and exclusively with the TV9p6-tetramer on day 41; only weak and poorly distinguished staining was observed with the TV9-tetramer. A similar pattern of low intensity staining was detected in the parallel TV9-8 culture, thereby indicating that the naive repertoire for TV9 from this individual might consist primarily of low avidity clonotypes. Thus, TV9p6 primed both TV9-specific clonotypes and a distinct non-cross-reactive population in this donor.

CD8 coreceptor dependence of cytotoxicity mediated by TV9- and TV9p6-CTL

Homogeneous TV9- and TV9p6-CTL cultures were assessed for their dependence on CD8 compensation using peptide-pulsed CIR target cells expressing WT HLA-A*0201 (CIRwt) or point-mutated HLA-A*0201 that cannot bind CD8 (CIRCD8null) [19] in chromium release cytotoxicity assays. Lysis of TV9-pulsed CIRCD8null cells by TV9-CTL was substantially reduced compared to lysis of TV9-pulsed CIRwt cells (Fig. 4A–D), thereby indicating that abrogation of CD8 binding impaired but did not obviate downstream functional activation. Figure 4E–H compare lysis mediated by parallel TV9p6-cultures over an effectual range of TV9p6 or TV9 peptide concentrations. TV9p6-T-cell cultures were equally cytotoxic to CIRwt cells pulsed with either peptide (filled symbols). Cytotoxicity was reduced without CD8 participation (open symbols), although this loss was markedly less pronounced for the cognate peptide in most cases. The use of paired target cells revealed that TV9p6-T cells exhibited greater intrinsic avidity than TV9-T cells for their cognate pMHCII complexes (p = 0.037; comparison of percent change in cytotoxicity at 10−7 M with CIR-A2wt versus CIR-A2CD8null cells for TV9-CTL and TV9p6-CTL using an unpaired two-tailed Student’s t-test) [20]. However, there was no significant difference between the CD8 dependencies of TV9-CTL and TV9p6-CTL with respect to lysis of target cells pulsed with the natural peptide. Importantly, these data show that CD8 binding to pMHCII can fully compensate for any “sensitivity” disadvantages associated with TV9 recognition in terms of the ability of TV9p6-T cells to kill in vitro.

Functional profile of TV9- and TV9p6-CTL

As polyfunctionality of HIV-specific CD8+ T cells appears to correlate with viral control in vivo [21, 22], the ability of cultured T cells to degranulate and secrete IL-2, TNF-α and IFN-γ was assessed after stimulation with peptide-pulsed CIR-A2wt cells (Table 3). Five of the six cultures were polyclonal, with tetramer1 cells staining with more than one TCR Vβ mAb; only TV9p6-1 was potentially monoclonal. The percentage of tetramer1 TV9- or TV9p6-T cells corresponded to that expressing surface CD107a/b upon antigen encounter. IFN-γ was produced by most CD107a/b-expressing cells, a proportion of which also produced IL-2 and

**Figure 2.** Evaluation of the ability of three agonist peptides (TV9p6, TV9p5 and TV9p29) listed in Table 1 to induce antigen-specific, TV9-cross-reactive CTL by in vitro immunization of naive CD8+ T cells from two to four healthy seronegative donors. Cultures are labeled as TV9pX-Y, where TV9pX identifies the inducing peptide and the numeral Y denotes a distinct donor. (A) TV9p6-6, TV9p6-2, TV9p6-5 and TV9p6-7; (B) TV9p5-3 and TV9p5-4; and (C) TV9p29-3 and TV9p29-8. CD8+ T cells were assayed for specificity and cross-recognition of TV9 using chromium release assays at effectortarget (E:T) ratios ranging from 20:1 to 0.6:1. T2 cells without peptide were included as negative controls in each assay. Data are shown as mean ± SEM of triplicate assays and are representative of two independent experiments; in most cases, the error bars are smaller than the plot symbols.
Table 2. Binding affinities of TV9 and its mimic peptides to HLA-A2 supertype molecules

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Sequence</th>
<th># Substitutions</th>
<th>IC50 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TV9</td>
<td>T L N A W V K V V Native</td>
<td></td>
<td>701</td>
</tr>
<tr>
<td>TV9p5</td>
<td>K I N A W I K G V 4</td>
<td></td>
<td>536</td>
</tr>
<tr>
<td>TV9p6</td>
<td>K I N A W I K V V 3</td>
<td></td>
<td>5120</td>
</tr>
<tr>
<td>TV9p29</td>
<td>T I N A W I K G V 3</td>
<td></td>
<td>1062</td>
</tr>
<tr>
<td>TV9p30</td>
<td>T I N A W I K V V 2</td>
<td></td>
<td>4228</td>
</tr>
<tr>
<td>SL9</td>
<td>S L Y N T V A T L Native</td>
<td></td>
<td>367</td>
</tr>
</tbody>
</table>

*Dash indicates IC50 > 10,000 nM.

TV9p6-CTL suppress HIV replication in vitro

The ability of TV9- and TV9p6-CTL to suppress replication of NL4-3.1 and JR-CSF in vitro was assessed (Fig. 6). Both viruses encode for TV9. Increasing suppression of NL4-3.1 replication in T1 cells on day 3 was observed with increasing E:T ratios of TV9-8 and TV9p6-8 CTL (Fig. 6A). Moreover, no significant difference in suppression was observed over the range of E:T ratios. Similar antiviral efficacy between four sets of parallel TV9- and TV9p6-CTL cultures was observed at two time points (Fig. 6B). Lastly, all CTL cultures inhibited the replication of JR-CSF in non-CD8+ PBMC (Fig. 6C). Thus, mimotope-primed CTL inhibited HIV replication in vitro at least as efficiently as those activated by the WT peptide.

TCRBV gene usage by parallel cultures of TV9- and TV9p6-CTL

To characterize further the nature of TV9- and TV9p6-CTL, we examined clonotype usage within TV9 tetramer-binding CD8+ T-cell populations in parallel cultures from several donors using a template-switch anchored RT-PCR to amplify all expressed TCRB gene products without bias as described previously [23] (Table 4). All TV9-CD8+ T-cell populations were oligoclonal, comprising six or fewer TCR clonotypes; distinct hierarchical frequencies were also apparent. Furthermore, despite starting naive T-cell pools derived from the same source, parallel TV9- and TV9p6-CTL cultures were largely distinct in terms of TV9-specific clonal composition. However, a degree of intra-individual clonal overlap was observed between TV9-6 and TV9p6-6 cultures and between TV9-7 and TV9p6-7 cultures (light shading, italicized sequences). Importantly, this demonstrates that at least some identical clonotypes were present within the initial naive T-cell pools and provides evidence that differential priming was not solely a result of stochastic “sampling” bias. Of note, a public clonotype, differentially encoded at the nucleotide level, was shared between two individuals (TV9p6-6 and TV9-9; darker shading, bold sequences).

Discussion

The value of using conserved regions of the HIV proteome for the purposes of vaccination has been recognized for some time [24–26]. However, although these domains are populated with CD8+ T-cell epitopes, most have not been correlated with protection in carriers of the majority of HLA class I alleles. We propose that the use of conserved regions within HIV as vaccines for non-protective class I alleles will depend on whether it is feasible to improve the intrinsic immunogenicity of these natural epitopes. This may be achieved by various means, such as modulating the usual patterns of immunodominance [27], improving processing and presentation [28, 29], or stimulating with mimotopes [14]. Indeed, there is suggestive evidence that protection can be achieved by vaccine-induced responses to a subdominant HLA-A*02-restricted epitope [30]. TV9 is an example of a conserved subdominant epitope with characteristics of a useful vaccine target. Our data with CTL primed in vitro from healthy donors revealed that it may be necessary to stimulate high avidity clonotypes selectively within the structurally diverse TV9-T cell precursor pools [11]. In this study, we identified and tested mimotopes of TV9 for the purpose of recruiting more appropriate HIV-specific CD8+ T cells. This approach is based on three principles: (i) a single TCR can respond to many different peptides [31]; (ii) the pool of precursor T-cell clonotypes specific for a particular epitope can be very diverse [32, 33]; and (iii) the requirements for T-cell priming and the triggering of downstream effector functions are different [34].
We screened a PS-SCL with a TV9-CTL culture to enable \textit{de novo} design of mimotopes that not only stimulate TV9-CTL but also immunize cross-reactive CTL \textit{in vitro}. The peptide library that we used consists of complex nonapeptide mixtures with one defined amino acid in one of the sequence positions and mixtures of all proteogenic amino acids excepting cysteine (which can be oxidized to crosslink peptides) in the remaining positions [35]. Up to $323 \times 10^9$ different peptides are represented in this library format. This strategy has been applied most extensively in autoimmune diseases and with promising clinical observations in cancer [36]. We have previously applied this approach to the “chronic immunodominant” HLA-A*0201-restricted SL9 (p17 Gag77–85) epitope and identified a mimotope that primed qualitatively superior CTL from the naive repertoires of healthy donors \textit{in vitro} and triggered more extensive expansion of antigen-experienced CD8$^+$ T cells from patients [14].

Very large numbers of mimotopes with different sequences and T-cell activation potencies can be identified for each epitope, with each mimotope addressing a different repertoire that intersects around the natural HIV epitope. Here, we specifically explored whether a variant peptide (TV9p6) with significantly lower binding affinity to HLA-A*0201 than the native epitope, presumably leading...
to a reduced pMHC density on the surface of APC, would focus the subdominant TV9-CTL response. In fact, a reciprocal relationship between binding affinity and functional sensitivity was recently reported for a cancer epitope and its agonist [37]. CTL cultures specific for TV9 and TV9p6 were almost always cross-reactive as determined by a shared capacity to lyse target cells loaded over a broad range of peptide concentrations, thereby suggesting considerable overlap between their recognition properties despite differences in three of nine positions between the two peptides. Moreover,CTL primed with both specificities consistently suppressed HIV replication in vitro, thereby indicating that they cross-recognized naturally processed and presented TV9. Although altered peptide ligands for other CTL epitopes can trigger differential responses [14], modification of the responding TCR repertoire by TV9p6 did not significantly alter any of the CTL functions or properties assessed, including antigen sensitivity measured by cytotoxicity or avidity measured by the intensity of tetramer staining. Moreover, the fact that highly functional CTL were generated by TV9p6 indicates that either CTL activation does not necessarily depend on peptide binding affinity to class I antigens or, alternatively, that the low binding affinity of TV9p6 to HLA-A*0201 exceeded a minimal threshold. Our finding is in line with recent reports showing that neither immunodominance nor the efficacy of CTL responses correlates with the binding affinity of the epitopic peptides to class I antigens [18, 38]. Indeed, substantially greater selection pressure on HIV is imposed by HLA-B compared to HLA-A alleles [17] despite the lower average peptide binding affinity of the former [18].

The quality of a virus-specific CD8⁺ T-cell response ultimately rests on the availability of "appropriate" clonotypes in the host T-cell repertoire [39]. In HIV infections, most studies have relied on the analysis of patient responses to infections in vivo. Although informative, they provide only partial insight into the diversity of the immune repertoire among individuals. Analysis of the pre-infection virus-specific T-cell pools will help complete the picture and may be particularly cogent for the design of prophylactic vaccines. For example, we noted a non-cross-reactive, TV9p6-tetramer binding population in one of the four donors shown in Fig. 3, indicating inter-individual differences in the intersection between the TCR repertoires specific for TV9 and TV9p6. This finding underscores the difficulty in selecting appropriate

---

**Table 3.** CD107a/b mobilization and production of cytokines after stimulation with TV9p6 or TV9 loaded onto C1R-A2⁺ cells in three sets of parallel CTL cultures

<table>
<thead>
<tr>
<th>CTL cultures (% tetramer⁺ cells)</th>
<th>Vβ Staining (% tetramer⁺ cells)</th>
<th>Stimulating peptide</th>
<th>% T cells in culture staining for</th>
</tr>
</thead>
<tbody>
<tr>
<td>TV9p6-1 (100)</td>
<td>Vβ2 (100)</td>
<td>TV9p6</td>
<td>CD107a/b 81 IL-2 33 CD107a/b 33 IFN-γ 81</td>
</tr>
<tr>
<td>TV9-1 (98)</td>
<td>Vβ8 (32), Vβ17 (19), Vβ21.3 (4), Vβ22.3 (4)</td>
<td>TV9</td>
<td>CD107a/b 81 IL-2 8 CD107a/b 8 IFN-γ 72</td>
</tr>
<tr>
<td>TV9p6-4 (52)</td>
<td>Vβ2 (40), Vβ8 (2), Vβ14 (1), Vβ21.3 (2)</td>
<td>TV9p6</td>
<td>CD107a/b 68 IL-2 20 CD107a/b 20 IFN-γ 48</td>
</tr>
<tr>
<td>TV9-4 (23)</td>
<td>Vβ8 (2), Vβ14 (1), Vβ22 (2), Vβ9 (14)</td>
<td>TV9</td>
<td>CD107a/b 61 IL-2 15 CD107a/b 15 IFN-γ 46</td>
</tr>
<tr>
<td>TV9p6-5 (40)</td>
<td>Vβ8 (3), Vβ12 (1), Vβ22 (4)</td>
<td>TV9p6</td>
<td>CD107a/b 44 IL-2 25 CD107a/b 25 IFN-γ 20</td>
</tr>
<tr>
<td>TV9-5 (57)</td>
<td>Vβ22 (50)</td>
<td>TV9</td>
<td>CD107a/b 25 IL-2 2 CD107a/b 2 IFN-γ 9</td>
</tr>
</tbody>
</table>

a) No staining was detected using an irrelevant peptide (YY9).

---

**Figure 5.** Functional sensitivity for two sets of parallel cultures determined by IFN-γ secretion. (A) TV9-2, (B) TV9p6-2, (C) TV9-8 and (D) TV9p6-8 cultures were stimulated at an E:T ratio of 1:10 with T2 cells pulsed with either TV9 or TV9p6. IFN-γ secretion into the supernatant was quantified by ELISA after 48h. (E) EC₅₀ values were calculated for the TV9 and TV9p6 peptides in each case with Graphpad Prism V software. Data are shown as mean ± SEM of triplicate assays and are representative of two independent experiments; in most cases, the error bars are smaller than the plot symbols.
epitope variants that will raise vigorous cross-reactive CD8$^+$ T cells without inadvertently activating responder cells that are not specific for the virus. These non-HIV responses can be potentially deleterious, perhaps working against the emergence of new responses to viral variants [40, 41]. On the other hand, subsequent HIV infection may selectively activate only the virus-specific memory pool generated by pre-emptive vaccination with mimotopes, thus promoting immunological control of HIV. The use of artificial sequences may be particularly important for “obligate” subdominant epitopes, which are recognized by intrinsically small T-cell precursor populations or suppressed by emerging T cells that target other epitopes. This study examines one strategy to heighten the intrinsic immunogenicity of known conserved subdominant determinants.

Molecular analysis of TCR$\beta$ gene expression showed that CTL cultures specific for TV9 and TV9p6 were oligoclonal and generally dominated by one or two clonotypes (Table 4). Although no TCR motifs were apparent, biased usage of certain sequences was found in two of three parallel cultures (TV9-6/TV9p6-6 and TV9-7/TV9p6-7). This suggests considerable clonal overlap and a high precursor frequency of certain cross-reactive clonotypes. Conservation within the CDR3 loop encoded distinctly at the nucleotide level was also detected between individuals, indicating a common antigen-specific “public TCR”. A recent study showed that usage of public clonotypes within a particular protective Gag-specific CD8$^+$ T-cell response in acute SIV infection can act as a molecular signature of biological outcome [42]. These findings emphasize the need to develop immunization strategies that selectively recruit efficacious epitope-specific CD8$^+$ T-cell clonotypes [43].

In summary, despite its low binding affinity to HLA-A$^*$0201, TV9p6 did not selectively mobilize high avidity clonotypes, although it did effectively activate fully functional HIV-specific CTL. Comparison of TCR$\beta$ gene usage between CD8$^+$ T-cell populations specific for TV9 and TV9p6 showed that distinct clonotypes were recruited in each case from the same initial naïve T-cell pool. Thus, mimotope-based vaccination represents a potentially viable approach to recruit additional cognate CD8$^+$ T-cell clonotypes that could overcome the intrinsic limitations of repertoire mobilization and thereby help to override natural patterns of epitope subdominance.

**Materials and methods**

**Healthy seronegative donors**

Heparinized blood was collected from healthy seronegative HLA-A$^*$0201$^-$ volunteers. High resolution HLA genotyping was performed at the Department of Transfusion Medicine, National Institutes of Health. This study was approved by the Human Investigation Committee at Wayne State University School of Medicine and the University of Texas at El Paso. All subjects provided written informed consent.
Generation of ex vivo primed peptide-specific CD8\(^+\) T-cell cultures from healthy seronegative donors

The procedures for the generation of peptide-specific CTL by in vitro immunization of naïve CD8\(^+\) T cells have been reported [44]. In brief, DC were derived from adherent peripheral blood monocytes after culturing for 7 days in complete medium (RPMI 1640 medium containing 10% autologous serum, 100 U/mL penicillin, 100 mg/mL streptomycin and 2 mM l-glutamine) supplemented with GM-CSF (1000 U/mL; Leukine Sargramostim, Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA) and IL-4 (500 U/mL; Peprotech, Rocky Hill, NJ, USA). Positively selected autologous CD8\(^+\) T cells (Dynabeads; Dynal) were primed with irradiated (4000 cGy) DC pulsed for 2h with 10 \(\mu\)g/mL peptide at a T cell–DC ratio of 5:1 in 48-well cluster plates. T cells were subsequently re-stimulated every 7–10 days with autologous monocytes pulsed with peptides [14, 44]. Ten ng/mL IL-7 (Genzyme) was added on the day of priming and re-stimulation; 20 U/mL IL-2 was added 1 and 4 days later.

Target cell lines

Cytotoxicity or intracellular cytokine secretion was assessed against peptide-pulsed T2 cells (TAP-deficient T-B lymphoblast hybrids [45]) or CIR cells expressing either full-length WT HLA-A\(^*\)0201 (CIR-A2\(^{wt}\)) or a point-mutated variant (CIR-A2\(^{CD8null}\)) that does not bind the CD8 coreceptor [46]. The HIV-1 replication-permissive T1 cell line expressing HLA-A\(^*\)0201 was used for viral suppression assays. All cell lines were maintained in RPMI with 10% heat-inactivated fetal calf serum.

Flow cytometric analysis

Directly conjugated mAb to CD8 (FITC- and PE-RPA-T8), CD107a (FITC-H4A3), CD107b (FITC-H4B4), HLA-A2 (FITC-BB7.2), IFN-\(\gamma\) (PE-B27), IL-2 (PE-MQ1-17H12) and TNF-\(\alpha\) (PE-MAb11) were purchased from BD Pharmingen (San Diego, CA, USA). \(\kappa\) family-specific mAb were obtained from Beckman Coulter (Miami, FL, USA). Tetramer stains were performed on ice for 30 min; cells were then washed and stained for CD8 at 4°C for an additional 20 min. Staining with an irrelevant tetramer was used as a control. Stained cells were acquired with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and data analyzed with WinMDI software. Intracellular cytokine production and degranulation were determined after stimulation for 4 h with peptide-pulsed (10 \(\mu\)g/mL) T2 or C1R cells at 37°C as described previously [47]. Gating was performed on CD8\(^+\) T cells and greater than 10,000 events were collected for each sample. TV9- and TV9p6-tetramers were obtained from the NIH Tetramer Core Facility (Atlanta, GA, USA).

Table 4. TCRBV and TCRJ usage, CDR3 amino acid sequence and percent frequency of TV9-specific CD8\(^+\) T cell clonotypes in parallel CTL cultures

<table>
<thead>
<tr>
<th>CTLs</th>
<th>HLA class I alleles</th>
<th>V(\kappa) (Arden) IMGT TRB CDR3 TRBJ Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>TV9-7</td>
<td>A(^*)0201,A11</td>
<td>13 6-1 CASSEEGAWNTGELF 2-2 90</td>
</tr>
<tr>
<td></td>
<td>B18,B27</td>
<td>9 3-1 CASSHTSGGLKDQTY 2-3 10</td>
</tr>
<tr>
<td>TV9p6-7</td>
<td>A(^*)0201,A29</td>
<td>7 4-3 CASPRGDWEEKAGELF 2-2 77</td>
</tr>
<tr>
<td></td>
<td>B40,B44</td>
<td>13 6-1 CASSEEGAWNTGELF 2-2 15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 29-1 CSVEDPDGRYEQY 2-7 8</td>
</tr>
<tr>
<td>TV9-6</td>
<td>A(^*)0201,A29</td>
<td>14 27 CASSRRGDGFQYPQH 1-3 36</td>
</tr>
<tr>
<td></td>
<td>B40,B44</td>
<td>13 6-6 CASSDFYNEQF 2-1 29</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 20-1 CASFSSGTGGVTGELF 2-2 14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7 4-3 CASSQDPSPSTDTQY 2-3 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 7-8 CASSLWGLADNEQF 2-1 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14 27 CASSLWGPPMEQY 2-5 7</td>
</tr>
<tr>
<td>TV9p6-6</td>
<td>A(^*)0201,A29</td>
<td>2 20-1 CASFSSGTGGVTGELF 2-2 82</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 7-2 CASSLVFQPGEEQY 2-7 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 20-1 CSAFSSGTGGVTGELF 2-2 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 20-1 CSAFSSGTGGVTGELF 2-2 6</td>
</tr>
<tr>
<td>TV9-9</td>
<td>A(^*)0201,A24</td>
<td>6 7-2 CASSLVFQPGEEQY 2-7 88</td>
</tr>
<tr>
<td></td>
<td>B15,B40</td>
<td>6 7-2 CASSLVFQGEFP 2-7 12</td>
</tr>
<tr>
<td>TV9-3</td>
<td>A2</td>
<td>3 28-0 CASSYRGQSYEQY 2-7 94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 29-1 CSGRGSYTEAF 1-1 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5, 31 CASSERYGQSYEQY 2-7 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 28-0 CASCRRGQSYEQY 2-7 1</td>
</tr>
<tr>
<td>TV9-2</td>
<td>A(^*)0201</td>
<td>2 20-1 CSAARDAGGYGT 1-2 69</td>
</tr>
<tr>
<td></td>
<td>B15,B40</td>
<td>8 12-4 CASSDTGEFL 2-2 26</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 3-1 CASSQVKIQGNEKLF 1-4 6</td>
</tr>
<tr>
<td>TV9p6-2</td>
<td>A(^*)0201</td>
<td>2 20-1 CSAARDAGDYGT 1-2 69</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 20-1 CSAARDAGDYGT 1-2 69</td>
</tr>
</tbody>
</table>
Nonapeptide library and assay for cytotoxicity with library mixtures

A TV9-CTL culture [11] was used to scan an l-amino acid nonapeptide PS-SCL to identify candidate mimotope sequences [14]. All nonapeptides present in the library were composed of a free N-terminus and an amidated C-terminus. The PS-SCL comprised 180 mixtures in an OX8 format, where O represents one of the 20 l-amino acids except l-cysteine at each of the remaining positions. Each mixture was composed of 1.7 × 10^10 peptides and the total X9 library consisted of some 323 × 10^9 different nonapeptides in approximately equimolar concentration. For stimulation of the index TV9-1, CTL were washed and resuspended at 1 × 10^5 cells/mL in complete medium 7 days after specific re-stimulation. Then, 100 μL of this cell suspension was added to triplicate wells of 96-well U-bottom plates containing 2 × 10^3 ^{51}Cr-labeled T2 cells and the various peptide library mixtures (100 μg/mL). Cells were cultured for 4 h at 37°C prior to harvesting and calculation of percent lysis determined with respect to control wells. Each mixture was assayed in triplicate and scanning was repeated three times. The library was prepared at Multiple Peptide Systems (San Diego, CA, USA).

Peptides

TV9 (TLNAWVKVV) and agonist peptides p30 (TINAWKVV), TV9p6 (KINAWIKVV), p29 (TINAWKGV) and p5 (KINAWIKGV) peptides were purchased at > 90% purity from Genemed Synthesis (San Francisco, CA, USA).

MHC-peptide binding assays

Quantitative assays to measure the binding of peptides to HLA A^*0201, A^*0202, A^*0203, A^*0206 and A^*6802 molecules were based on the inhibition of binding of a radiolabeled standard peptide as described previously [48]. Peptides were tested at six different concentrations in three or more independent assays and the concentration of peptide yielding 50% inhibition of the binding of the radiolabeled probe peptide (IC_{50}) was calculated. Under the conditions used, where [radiolabeled probe] < [MHC] and IC_{50} ≥ [MHC], the measured IC_{50} values are reasonable approximations of the true K_d values.

IFN-γ detection by ELISA

IFN-γ secretion was determined by ELISA with an OptEIA Set (BD Pharmingen) in supernatants of T cells re-stimulated with peptide-pulsed T2 cells for 48 h. The range of sensitivity for IFN-γ was 15–500 pg/mL. EC_{50} values (concentrations of peptide required to elicit 50% of the maximal reactivity) were calculated with GraphPad Prism V software.

In vitro viral suppression assays

The capacity of TV9-CTL to inhibit HIV infection was determined in vitro. HIV JR-CSF and NL4-3.1 stocks were generated and titers were determined as previously described [49]. Infected PBMC or T1 cells (infected by NL4-3.1 virus at 500 pg p24 per 10^6 cells) were cultured at 50,000 cells per flat-bottomed well in 96-well plates with CTL at the indicated ratios in complete medium containing IL-2 (25 U/mL). PBMC from HLA-A^*0201^+ , HIV-uninfected donors were depleted of CD8^+ cells (Miltenyi Biotec, Auburn, CA, USA), activated with phytohemagglutinin A in complete medium containing IL-2 (25 U/mL) for 2 days and then infected by overnight incubation with HIV JR-CSF at 80 TCID_{50}/mL (GenBank Accession Number AAB05598). Supernatants were tested for p24 antigen concentration by ELISA (HIV-1 p24CA antigen capture assay kit, AIDS and Cancer Virus Program, NCI Frederick Cancer Research) every 3 days up to day 9. The range of sensitivity for p24 was 7.5–400 pg/mL.

Molecular analysis of expressed TCRB gene products by quantitative clonotypic PCR

Tetramer-binding CD8^+ T cells were sorted viably to > 98% purity for RNA-based analysis of TCRB gene expression using an unbiased template-switch anchored RT-PCR as described previously [23]. The IMGT nomenclature is used for all molecular analyses conducted in this study.

Acknowledgements: This study was supported by the Michigan Life Sciences Corridor Program 1659 (J. K.-M.), NIH R01-AI064069 and R01-AI77413 (J. K.-M.), and NCRR 5G12RR008124 (J. K.-M.). We acknowledge support to S. E. B. and D. B. W. from the AIDS and Infectious Disease Science Center, NIH R43DA021175 (S. E. B.) and NIH R44DA015212 (D. B. W.). D. A. P. is a Medical Research Council (UK) Senior Clinical Fellow.

Conflict of interest: The authors declare no financial or commercial conflict of interest.

References


Abbreviations: Tetramer: tetrameric HLA-A201-peptide complex
TV9: HIV p24 Gag19–27 epitope (TLNAWVKVV)